Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Issue 3 (4th March 2017)

• Record Type: Journal Article
• Authors: Hong, Eva; Terrade, Aude; Taha, Muhamed-Kheir
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 3(2017)
• Page Start: 645
• Page End: 648
• Publication Date: 2017-03-04
• Subjects: immunogenicity -- laboratory workers -- Neisseria meningitidis -- vaccine -- safety; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2016.1241358
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.